AbbVie Inc. (NYSE: ABBV) kicked off on May 19, 2023, at the price of $143.86, up 1.16% from the previous trading day. During the day, the shares moved up to $145.80 and dropped to $143.80 before settling in for the closing price of $143.44. Over the past 52 weeks, ABBV has traded in a range of $134.09-$168.11.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 15.50%. While this was happening, its average annual earnings per share was recorded 2.70%. With a float of $1.76 billion, this company’s outstanding shares have now reached $1.77 billion.
The extent of productivity of a business whose workforce counts for 50000 workers is very important to gauge.
AbbVie Inc. (ABBV) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of AbbVie Inc. is 0.13%, while institutional ownership is 70.90%. The most recent insider transaction that took place on Apr 25, was worth 1,011,450. In this transaction SVP, US COMMERCIAL OPERATIONS of this company sold 6,130 shares at a rate of $165.00, taking the stock ownership to the 35,330 shares. Before that another transaction happened on Apr 17, when Company’s SVP, US COMMERCIAL OPERATIONS sold 7,499 for $161.67, making the entire transaction worth $1,212,338. This insider now owns 35,330 shares in total.
AbbVie Inc. (ABBV) Latest Financial update
In the latest quarterly report, which was put into the public domain on 3/30/2023, the organization reported $2.46 earnings per share (EPS), higher than consensus estimate (set at $2.46) by $0. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.70% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.20% during the next five years compared to 13.30% growth over the previous five years of trading.
AbbVie Inc. (NYSE: ABBV) Trading Performance Indicators
Take a look at AbbVie Inc.’s (ABBV) current performance indicators. Last quarter, stock had a quick ratio of 0.80. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.46. Likewise, its price to free cash flow for the trailing twelve months is 18.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 4.24, a number that is poised to hit 2.93 in the next quarter and is forecasted to reach 11.07 in one year’s time.
Technical Analysis of AbbVie Inc. (ABBV)
The latest stats from [AbbVie Inc., ABBV] show that its last 5-days average volume of 4.99 million was inferior to 5.89 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 40.52%. Additionally, its Average True Range was 2.80.
During the past 100 days, AbbVie Inc.’s (ABBV) raw stochastic average was set at 16.64%, which indicates a significant decrease from 31.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 13.87% in the past 14 days, which was lower than the 21.81% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $154.90, while its 200-day Moving Average is $150.70. Now, the first resistance to watch is $146.01. This is followed by the second major resistance level at $146.90. The third major resistance level sits at $148.01. If the price goes on to break the first support level at $144.01, it is likely to go to the next support level at $142.90. The third support level lies at $142.01 if the price breaches the second support level.
AbbVie Inc. (NYSE: ABBV) Key Stats
The company with the Market Capitalisation of 253.07 billion has total of 1,764,290K Shares Outstanding. Its annual sales at the moment are 58,054 M in contrast with the sum of 11,836 M annual income. Company’s last quarter sales were recorded 12,225 M and last quarter income was 239,000 K.
